Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Nilsson

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Current Cancer Drug Targets|June 30, 2020
Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINELSven Nilsson, Alexander Stein, Christian Rolfo, et al.
Disaster Medicine and Public Health Preparedness|September 6, 2017
Lessons Learned From Implementing an Incident Command System During a Local Multiagency Response to a Legionnaires' Disease Cluster in Sydney, NSWEmma Quinn, Travers Johnstone, Zeina Najjar, et al.
International Journal of Integrated Care|October 17, 2022
Sydney Local Health District's Integrated Response to the COVID-19 Pandemic: A Descriptive StudyDarith Liu, Hueiming Liu, Lou-Anne Blunden, et al.
BMC Cancer|June 4, 2020
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)Joseph Tintelnot, Eray Goekkurt, Mascha Binder, et al.
Gastroenterology|June 26, 2020
IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and HumansJan Kempski, Anastasios D Giannou, Kristoffer Riecken, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Current Cancer Drug Targets|June 30, 2020
Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINELSven Nilsson, Alexander Stein, Christian Rolfo, et al.
Disaster Medicine and Public Health Preparedness|September 6, 2017
Lessons Learned From Implementing an Incident Command System During a Local Multiagency Response to a Legionnaires' Disease Cluster in Sydney, NSWEmma Quinn, Travers Johnstone, Zeina Najjar, et al.
International Journal of Integrated Care|October 17, 2022
Sydney Local Health District's Integrated Response to the COVID-19 Pandemic: A Descriptive StudyDarith Liu, Hueiming Liu, Lou-Anne Blunden, et al.
BMC Cancer|June 4, 2020
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)Joseph Tintelnot, Eray Goekkurt, Mascha Binder, et al.
Gastroenterology|June 26, 2020
IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and HumansJan Kempski, Anastasios D Giannou, Kristoffer Riecken, et al.
Pageof 2